05:05:00Philippines

Dare Bioscience, Inc. (DARE)

NASDAQ

Key stats Fiscal year 2025

Income statement

Revenue
1,030,193 10429.4%
Net income
-13,400,000
Operating income
-13,552,334
Earnings per share
-1.20
R&D expense
5,523,352

Growth and profitability

Operating margin
-1,315.51
Net margin
-1,300.73
Return on equity
-471.39
Return on assets
-41.26
Free cash flow margin
-997.01

Balance sheet

Total assets
32,474,563
Total liabilities
29,631,929
Shareholders' equity
2,842,634
Cash and equivalents
24,711,356
Current ratio
1.14

Cash flow and ratios

Operating cash flow
-9,885,870
Free cash flow
-10,271,148

Shareholder returns

Shares outstanding
15,289,502
Book value per share
0.19
Revenue and net income
From revenue to profit 2025
Debt, free cash flow and cash
Earnings per share

Company information

Headquarters
San Diego, CA
Exchange
NASDAQ
Fiscal year end
12-31
Industry (SEC)
Pharmaceutical Preparations

Fiscal year end: · Source: SEC EDGAR

Dare Bioscience, Inc. trades on NASDAQ under the ticker symbol DARE. This page brings together its price chart, company profile, key financial figures and technical indicators.

Company profile

Technical analysis